{
    "nctId": "NCT01382667",
    "briefTitle": "Plasma Levels of Glucagon-like Peptide-2 and Dyspepsia in Patients With Extraintestinal Cancer During Chemotherapy",
    "officialTitle": "Evaluation of Dyspeptic Symptoms in Oncological Frail Patients With Extraintestinal Cancer in Chemotherapy. Assessment of Circulating Levels of Glucagon-like Peptide 2 (GLP-2) in Relation to Mucositis",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Lung Cancer, Dyspepsia",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 70,
    "primaryOutcomeMeasure": "GLP-2 plasma levels in cancer patients",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with newly diagnosed cancer (lung and breast cancer),\n* Patients currently free of active disease\n\nExclusion Criteria:\n\n* History of cerebral edema, primary and secondary brain neoplasm with signs and symptoms of raised intracranial pressure and/or brain metastases,\n* Signs of marked hepatic or renal dysfunction, cardiac failure\n* Signs of dyspepsia, peptic ulcer, gastric surgery or prior diagnosis of other cancer\n* Administration of drugs interfering with GI motility (i.e. antisecretory, prokinetic, or antibiotic drugs) as well as the exposition to radiotherapy, four weeks prior to the examination\n* Referred episode of nausea of any severity within 24 h prior to antiemetic therapy, if they had experienced vomiting in the previous 24 h,\n* Pregnancy or lactating\n* Concomitant administration of agents known to have significant antiemetic activity, including benzodiazepines and other corticosteroids",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}